Dr. Andrew Willeford, PharmD, PhD, BCCP

Health Sciences Assistant Clinical Professor
Skaggs School of Pharmacy and Pharmaceutical Sciences

Andrew Willeford, PharmD, PhD, BCCP

Human Resources

Mandi Garhartt (formerly Walker)


Danise Adrianzen Talavera

Research Summary

Dr. Willeford’s research focuses on strategies to improve medication implementation for cardiomyopathies including heart failure with reduced ejection fraction and hypertrophic cardiomyopathy. Current research includes evaluating clinical outcomes of a pharmacist-led virtual titration clinic in patients with heart failure. Other work involves creating best-practice models for utilization of cardiac myosin inhibitors for the treatment of obstructive hypertrophic cardiomyopathy.

Academic Achievements

Education: Doctor of Philosophy in Biomedical Sciences, UC San Diego (2017); Doctor of Pharmacy, UC San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences (2019); PGY1 Acute Care Pharmacy Residency, UC San Diego Health (2020); PGY2 Cardiology Pharmacy Residency, University of Maryland School of Pharmacy (2021); Board Certification in Cardiology Pharmacy (2021)

Awards and Honors: University of California San Diego Department of Pharmacology Roland K. Robins Outstanding Thesis Award (2018); Society of Pain and Palliative Care Pharmacists Renee Holder Literature Award (2020)

  • Co-Chair, Therapeutics (SPPS 212B)
  • Chair, Pharmacotherapy and Diseases (DDPM 201)
  • Co-Chair, Dosage Forms, Non-Sterile Compounding Lab (SPPS 225)
Key Contributions
  • Collaborated in establishing a pharmacist-led virtual guideline-directed medical therapy titration clinic
  • Designed a model for prescribing and management of mavacamten in obstructive hypertrophic cardiomyopathy
  • Developed a heart failure clinic rotation for pharmacy residents and students
  • Elucidated pathways by which calcium/calmodulin-dependent protein kinase II delta mediates cardiac inflammation through the NLRP3 inflammasome
Potential Collaborative Programs
  • Guideline-directed medical therapy implementation strategies
  • Hypertrophic cardiomyopathy therapy management